US 11,857,552 B2
4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors
Ash Bahl, Dublin (IE); Ed Ainscow, Dublin (IE); Alexander Bondke, Caputh (DE); Anthony G. M. Barrett, Rio de Janeiro (BR); Mihiro Sunose, Nottingham (GB); Jason John Shiers, Nottingham (GB); and Kamaldeep Chohan, Nottingham (GB)
Assigned to CARRICK THERAPEUTICS LIMITED, Dublin (IE)
Appl. No. 16/648,011
Filed by Carrick Therapeutics Limited, Dublin (IE); Cancer Research Technology Limited, London (GB); and IP2IPO Innovations Limited, London (GB)
PCT Filed Sep. 20, 2018, PCT No. PCT/EP2018/075482
§ 371(c)(1), (2) Date Mar. 17, 2020,
PCT Pub. No. WO2019/057825, PCT Pub. Date Mar. 28, 2019.
Claims priority of application No. 1715194 (GB), filed on Sep. 20, 2017.
Prior Publication US 2020/0345736 A1, Nov. 5, 2020
Int. Cl. A61K 31/519 (2006.01); A61K 33/243 (2019.01); A61K 31/138 (2006.01); A61K 31/337 (2006.01); A61K 31/4196 (2006.01); A61K 31/513 (2006.01); A61K 31/517 (2006.01); A61K 31/565 (2006.01); A61K 31/5685 (2006.01); A61K 31/675 (2006.01); A61K 31/704 (2006.01); A61K 31/7068 (2006.01); C07D 487/04 (2006.01); A61K 39/395 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 31/138 (2013.01); A61K 31/337 (2013.01); A61K 31/4196 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/565 (2013.01); A61K 31/5685 (2013.01); A61K 31/675 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 33/243 (2019.01); A61K 39/3955 (2013.01); C07D 487/04 (2013.01)] 6 Claims
 
1. A compound selected from compounds of the following formulae, or a pharmaceutically acceptable salt thereof:

OG Complex Work Unit Chemistry